

MINISTRY OF HEALTH

PHARMACY AND POISONS BOARD

RAPID ALERT NOTIFICATION OF A QUALITY DEFECT/RECALL

		Reference Number : 2024/002	
1. To: World Health Organisation, Market Autorisation Holders, Distributors, Retailers and Consumers			
2. Product Class of Defect: Class I		3. Falsification	
4. Product : Herceptin 440mg (<i>Trastuzumab 440mg</i>)	5. Marketing Authorisation Number :20372For use in humans		
6. Brand/Trade Name : Herceptin 440mg	7. INN or Generic Name : Trastuzumab 440mg		
8. Dosage Form : Injection	9. Strength : 440mg		
10. Batch Number : C5830083	11. Expiry Date : 11/2024.		
12. Pack size and Presentation: 1 Vial	13. Date Manufactured : 12/2021		
14. Marketing Authorisation Holder: F. Hoffman-La Roche Ltd			
15. Manufacturer : Claimed to be manufactured in Germany by Roche Products Ltd			
Contact Person: Not Applicable			
Telephone: Not Applicable	16. Recallir Applicable	ng Firm (if different) : Not	
15.1 Where the defect is attributed to a manufacturing site, site where defect	Contact Per	rson: Not Applicable	
occurred (if different from 15): Not Applicable	Telephone:	Not Applicable	
Contact Person: Not Applicable			
Telephone: Not Applicable			
17. Recall Number Assigned (if available): Not Applicable			

18. Details of Defect/Reason for Recall : **The Pharmacy and Poisons Board** "the board" received an alert from the market concerning the falsification of Herceptin 440mg (*Trastuzumab 440mg*) where the product batch was claimed to be manufactured in Germany by Roche Products Ltd.

19. Information on distribution including exports (type of customer, e.g. hospitals): **Not Applicable**

20. Action taken by Issuing Authority : The Board has initiated a rapid response and heightened surveillance to verify whether the falsified Herceptin 440mg (*Trastuzumab 440mg*) is presently circulating in the Kenyan market.

21. Proposed Action : The Board cautions the public and healthcare professionals AGAINST trading, distribution, wholesaling, retailing, issuing, dispensing, use or administration to patients of the falsified Herceptin 440mg (*Trastuzumab* 440mg Batch C5830083, as such actions are illegal and jeopardise public health and safety. The Board encourages the public and healthcare professionals to immediately share any information regarding Herceptin 440mg (*Trastuzumab* 440mg with the Pharmacy and Poisons Board.

22. From (Issuing Authority):	23. For Feedback
Kenya Pharmacy and Poisons	
Board	Contact: pms@ppb.go.ke
	Telephone: 0795743049
24. Date : 11th May 2024	